APOBEC3C‐mediated NF‐κB activation enhances clear cell renal cell carcinoma progression

• Published in: Molecular oncology Vol. 19; no. 1; pp. 114 - 132
• Main Authors: Hase, Nora, Misiak, Danny, Taubert, Helge, Hüttelmaier, Stefan, Gekle, Michael, Köhn, Marcel
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.01.2025; John Wiley and Sons Inc; Wiley
• Subjects: Animals; APOBEC3C; Apolipoproteins; Carcinoma, Renal cell; Carcinoma, Renal Cell - genetics; Carcinoma, Renal Cell - metabolism; Carcinoma, Renal Cell - pathology; ccRCC; Cell activation; Cell Line, Tumor; Cell survival; Cells; Clear cell-type renal cell carcinoma; Cloning; CRISPR; Cytidine Deaminase - genetics; Cytidine Deaminase - metabolism; Cytoplasm; Development and progression; Disease Progression; Enzymes; Gene expression; Gene Expression Regulation, Neoplastic; Genes; Genomes; Genomics; Humans; Hypoxia; Immune system; Immunotherapy; Inflammation; Kidney cancer; Kidney Neoplasms - genetics; Kidney Neoplasms - metabolism; Kidney Neoplasms - pathology; Messenger RNA; Metastases; Mice; Mice, Nude; Molecular modelling; Mutation; NF-kappa B - metabolism; NF-κB Signalling; NF‐κB; Phosphorylation; Plasmids; Protein binding; Proteins; RBP; Renal Cancer; RNA editing; RNA sequencing; RNA-binding protein; Signal Transduction; Transcription factors; Tumor cell lines; Tumors; United States; Germany; Newfoundland and Labrador; United States > US; APOBEC3C; RBP; NF‐κB; ccRCC

Renowned as the predominant form of kidney cancer, clear cell renal cell carcinoma (ccRCC) exhibits susceptibility to immunotherapies due to its specific expression profile as well as notable immune cell infiltration. Despite this, effectively treating metastatic ccRCC remains a significant challeng...